Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and the promotion of tumorigenesis in cancers, novel compounds endowed with histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. Indeed, the potential of HDAC inhibitors for cancer therapy has been explored in preclinical models, and some agents approved for hematologic malignancies have reached the clinical setting. HDAC inhibitors are able to mediate the induction of both apoptosis and autophagy, which are related to anticancer activity in a variety of cancer cell lines. Given the inherent resistance to apoptosis that characterizes cancer, the targeting of alternative pathways is an attractive strategy to improve anti‐tumor therapy. The activation of autophagy represents novel cancer treatment targets. This paper aims to critically discuss how the anticancer potential of HDAC inhibitors may elicit a response to human cancers through different cell pathways leading to cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“Hydroxamic acids (TSA, SAHA, LAQ824, and CBHA) and pyroxamic acids (PXD101 and CRA-026440) are panHDAC inhibitors targeting class I, II, and IV HDACs in the nanomolar range [17].”
BackgroundCell death modalities: classification and pathophysiological implications
Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402148 · Cited by 832 · cited 1×
“Type III cell death (necrosis) is characterized by oncosis and plasma membrane rupture [20].”
BackgroundHDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy
Lee, J., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.405 · Cited by 756 · cited 1×
“The ubiquitin-binding deacetylase, HDAC6, was also identified as a central component of basal autophagy that targets protein aggregates and damages mitochondria; however, HDAC6 is not required for autophagy activation; rather, it controls the fusion of autophagosomes to lysosomes [38].”
BackgroundWilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · cited 1×
“Recently, silencing of HDAC3 has been found to induce the expression of p21 and cell cycle arrest in the G2/M phase in colon cancer cells [42].”
Background
Cited by
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Selenium Compounds, Apoptosis and Other Types of Cell Death: An Overview for Cancer Therapy
Sanmartín, C., Plano, D., Sharma, A. K., & Palop, J. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089649 · Cited by 274
The emerging role of acetylation in the regulation of autophagy
Bánréti, Á., Sass, M., & Graba, Y. (2013) · Autophagy · doi:10.4161/auto.23908 · Cited by 164
Metadata
- Authors
- Rikiishi, H.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 2011
- Issue
- 1
- Pages
- 830260-830260
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2164713773
- Cited by
- 94
- References
- 5
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.